PharmaMar presents encouraging results at ASCO for Small Cell Lung Cancer
-
PharmaMar is a biotech company world leader in the discovery, development, and commercialization of marine-derived cancer drugs. -
More than half of the patients, 52,7%, in a PharmaMar study attained an objective response (tumour shrinkage of ≥30%) from a combination treatment for Small Cell
Lung Cancer with a chemotherapy-free interval greater than 30 days responded to treatment. -
The study was presented at the world's largest clinical oncology congress held in
Chicago, USA betweenMay 31 st andJune 4 th.
Regarding this disease, the results presented by the company at ASCO show that the combination of its drug for this pathology, Zepzelca® (lurbinectedin), in combination with irinotecan produces a synergy that enhances the activity of lurbinectedin, resulting in high and durable response rates in populations that are sensitive, with a chemotherapy-free interval greater than 90 days (CTFI> 90 days), and platinum-resistant with a chemotherapy-free interval of less than 90 days (CTF< 90 days).
Particularly encouraging are the data drawn from the subgroup of 74 patients with a chemotherapy-free interval greater than 30 days (CTFI>30 days) with a response rate of 52.7% and a median response duration of 7.6 months.
Among the study data within this subgroup, the overall survival (OS) data is also encouraging, with a median of 12.7 months. The safety profile has proven to be manageable with a low percentage of treatment interruptions.
Zepzelca® (lurbinectedin) is a synthetic compound derived from the tunicate Ecteinascidia turbinata found by
One of the confirmatory studies, LAGOON, consists of three arms, one of which is lurbinectedin with irinotecan. The results presented at ASCO reinforce the rationale for including this combination as an experimental arm with this type of patient in this ongoing pivotal trial.
Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About
PM1183-A-014-15
PM1183-A-014-15 is a multicenter, open-label Phase I/II Basket study of lurbinectedin in combination with irinotecan in relapsed first lines patients. The study enrolled 101 patients in the SCLC cohort, and the results showed a good outcome in this patient population, included in one arm of the lurbinectedin plus irinotecan combination of the LAGOON study. These results refer to the Overall Response Rate (ORR), Duration of Response (DoR), Progression-Free and Overall Survival (PFS and OS), along with a manageable safety and tolerability profile.
About Zepzelca®
Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.
Photo - https://mma.prnewswire.com/media/2429110/PharmaMar_1.jpg
Logo - https://mma.prnewswire.com/media/2429111/PharmaMar_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/pharmamar-presents-encouraging-results-at-asco-for-small-cell-lung-cancer-302162539.html
![](https://rt.prnewswire.com/rt.gif?NewsItemId=EN30002&Transmission_Id=202406040300PR_NEWS_EURO_ND__EN30002&DateId=20240604)